An AI drug discovery company aiming to unlock tens of thousands of previously undruggable targets, Serinus Biosciences has closed a $1.1M seed round. The startup specializes in designing small molecule disrupters for protein-protein interactions (PPIs), a notoriously challenging area in drug development.
Serinus Biosciences leverages a proprietary proteome-wide interface energetics map to transform natural protein ligands into small molecule binding opportunities. Its PPI-specific generative AI engine is designed to accelerate the discovery of potent, synthetically accessible interface binding hits, reducing development timelines from years to months.















